Baseline characteristics and predictors of outcome in patients with myelodysplastic syndromes living in Western Pennsylvania

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 265-272

  Mutetwa, Batsirai ^a   Fryzek, Jon ^b   Du, Yan ^c   Yong, Mellissa ^d   Sekeres, Mikkael A ^e   Taioli, Emanuela ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b MEDIMMUNE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d AMGEN INC   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bone marrow failure; Cancer registry; Epidemiology; MDS

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; DISEASE COURSE; FAMILY HISTORY; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTE COUNT; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PENNSYLVANIA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79551625654     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.540726     Document Type: Article

References (41)

1. Du Y, Fryzek J, Sekeres MA, Taioli E. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res 2010;34:1-5.
2. Farrow A, Jacobs A, West RR. Myelodysplasia, chemical exposure, and other environmental factors. Leukemia 1989;3:33-35.
3. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-1551.
4. Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med 2010;77:37-44.
5. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
6. Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996;94:116-119.
7. West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res 1995;19:127-139.
8. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83:71-86.
9. Hasle H, Baumann I, Bergstrasser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004;18:2008-2014.
10. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
11. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
12. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385-4395.
13. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
14. Haase D, Germing U, Schanz J, et al. New and comprehensive cytogenetic prognostication and categorization in MDS. Blood 2006;108(Suppl. 1): Abstract 248.
15. Haase D, Germing U, Schanz J, et al. Evidence for an underestimation of the prognostic impact of poor cytogenetics within the IPSS. Blood 2006;108(Suppl. 1): Abstract 252.
16. Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. Leuk Lymphoma 2008;49:427-438.
17. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008;83:765-770.
18. Horwich TB, Fonarow GC, Hamilton MA, Maclellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-1786.
19. Nguyen P. The myelodysplastic syndromes. Hematol Oncol Clin North Am 2009;23:675-691.
20. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
21. Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 2005;19:1912-1918.
22. Strom SS, Velez-Bravo V, Estey EH. Epidemiology of myelodysplastic syndromes. Semin Hematol 2008;45:8-13.
23. Bjork J, Albin M, Mauritzson N, Stromberg U, Johansson B, Hagmar L. Smoking and myelodysplastic syndromes. Epidemiology 2000;11:285-291.
24. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008;93:1712-1717.
25. Sperr WR, Wimazal F, Kundi M, et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 2001;80:272-277.
26. Zhao WL, Xu L, Wu W, et al. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution. Hematol J 2002;3:137-144.
27. Lee JJ, Kim HJ, Chung IJ, et al. Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leuk Res 1999;23:425-432.
28. Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, Le Beau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986;67:1765-1772.
29. Gyger M, Infante-Rivard C, D'Angelo G, Forest L, Lussier P. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes. Am J Hematol 1988;28:13-20.
30. Tricot G, Boogaerts MA, DeWolf-Peeters C, Van den Berghe H, Verwilghen RL. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 1985;59:659-670.
31. Tricot G, Vlietinck R, Boogaerts MA, et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 1985;60:19-32.
32. Chen BA, Gao C, Ding J, et al. [Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009;17: 1472-1476.
33. Parlier V, van Melle G, Beris P, et al. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet 1994;78:219-231.
34. Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol 1994;46:270-277.
35. Suciu S, Kuse R, Weh HJ, Hossfeld DK. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 1990;44:15-26.
36. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;7:1315-1323.
37. Mirza I, Garzon R, Burns J, Edwards L, Fernandez-Cymering C, Kloss R. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System. Conn Med 2001;65: 455-463.
38. Belli C, Acevedo S, Bengio R, et al. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica 2002;87:9-16.
39. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010;28:2847-2852.
40. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008;87:691-699.
41. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009;39:548-553.